-
GAD65 antibody neurologic syndrome presenting with hemiparkinsonism
-
Gait and motion analysis in Progressive Supranuclear Palsy
-
Gait and turning alterations in idiopathic REM sleep behavioral disorder and early Parkinson’s disease: a cross-sectional study with mobile health technology
-
Gait initiation in patients with Progressive Supranuclear Palsy: a biomechanical and FDG-PET study
-
GCH1 variants contribute to risk and earlier age at onset in Parkinson’s disease
-
GCI-induced neurodegeneration and synucleinopathy in non-human primates
-
Gender differenes in cognitive functioning in de novo Parkinson’s disease patients
-
Gender-related differences in nonmotor symptoms in the context of subthalamic stimulation in Parkinson’s disease
-
Genetic analysis of Huntington’s Disease in a Brazilian Amazonian population
-
Genetic and environmental prognostics of cognitive trajectories in patients with Parkinson’s disease
-
Genetic Profiling of Early Synucleinopathy in Rat Nigrostriatal Dopamine Neurons
-
Genetic risk scores and hallucinations in Parkinson’s disease patients
-
Genetic testing in pediatric dystonia and influence of clinical factors on diagnostic yield
-
Genetic, biochemical and clinical findingss in Friedreich’s ataxia patients – relationship with the disease severity
-
Genome-wide association studies of progression in Parkinson’s disease
-
Gerstmann-Sträussler-Scheinker disease presenting as a late onset slowly progressive spinocerebellar ataxia: expanding the phenotypic spectrum of genetic prion disease
-
Glucocerebrosidase activity and atypical parkinsonism: a multi-centre exploratory study
-
Glucocerebrosidase Deficiency Mediates Propagation of Protein Aggregation via Extracellular Vesicle Dysregulation
-
Goalkeeper Game: a new assessment tool for prediction of gait performance under complex condition in people with Parkinson’s disease
-
Gpi Deep Brain Stimulation After Many Years of Subthalamic Nucleus Stimulation: Case Report
-
GPNMB protein levels in CNS are modulated by PD risk variant rs199347
-
Graph theory analysis of dopamine D2 receptor network in Parkinson’s disease patients
-
Gut Microbiota in Parkinson’s disease: influences of device-assisted therapies
-
Gut Microbiote Distinctive Features and Microbiota-Metabolome Profile in Parkinson’s Disease: Focus on Levodopa and LCIG
-
GWAS on impulse control disorders in Parkinson’s disease
MDS Virtual Congress 2020
September 12-16, 2020. Virtual Congress. www.mdscongress.org